June 7, 2017 / 5:27 PM / a month ago

BRIEF-Cerenis Therapeutics announces positive results from CER-209 phase I single dose tolerance study for NAFLD and NASH

1 Min Read

June 7 (Reuters) - CERENIS THERAPEUTICS HOLDING SA:

* CERENIS THERAPEUTICS: POSITIVE RESULTS FROM THE CER-209 PHASE I SINGLE DOSE TOLERANCE STUDY FOR NAFLD AND NASH

* COMPLETION OF SINGLE DOSE TOLERANCE STUDY (SDT) FOR CER-209

* No Drug Related Safety Nor Tolerance Issues Identified

* Multiple Dose Tolerance Study (Mdt) Now Ready to Proceed

* PHARMACOKINETICS OBSERVATIONS SUPPORT CER-209 ONCE DAILY ORAL DOSING Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below